收费全文 | 380089篇 |
免费 | 33614篇 |
国内免费 | 14816篇 |
耳鼻咽喉 | 2858篇 |
儿科学 | 7798篇 |
妇产科学 | 6889篇 |
基础医学 | 58408篇 |
口腔科学 | 7930篇 |
临床医学 | 29889篇 |
内科学 | 60002篇 |
皮肤病学 | 6600篇 |
神经病学 | 32116篇 |
特种医学 | 7716篇 |
外国民族医学 | 105篇 |
外科学 | 27530篇 |
综合类 | 54601篇 |
现状与发展 | 53篇 |
一般理论 | 18篇 |
预防医学 | 21778篇 |
眼科学 | 5982篇 |
药学 | 53085篇 |
97篇 | |
中国医学 | 13604篇 |
肿瘤学 | 31460篇 |
2024年 | 307篇 |
2023年 | 5519篇 |
2022年 | 7773篇 |
2021年 | 14538篇 |
2020年 | 12862篇 |
2019年 | 11538篇 |
2018年 | 11381篇 |
2017年 | 11938篇 |
2016年 | 12484篇 |
2015年 | 13956篇 |
2014年 | 22117篇 |
2013年 | 26614篇 |
2012年 | 22224篇 |
2011年 | 25355篇 |
2010年 | 21181篇 |
2009年 | 21218篇 |
2008年 | 21334篇 |
2007年 | 20489篇 |
2006年 | 18364篇 |
2005年 | 16240篇 |
2004年 | 14016篇 |
2003年 | 12409篇 |
2002年 | 10156篇 |
2001年 | 8670篇 |
2000年 | 7440篇 |
1999年 | 6310篇 |
1998年 | 5312篇 |
1997年 | 5042篇 |
1996年 | 4507篇 |
1995年 | 4586篇 |
1994年 | 4060篇 |
1993年 | 3506篇 |
1992年 | 2996篇 |
1991年 | 2705篇 |
1990年 | 2249篇 |
1989年 | 1932篇 |
1988年 | 1689篇 |
1987年 | 1436篇 |
1986年 | 1315篇 |
1985年 | 1947篇 |
1984年 | 1768篇 |
1983年 | 1197篇 |
1982年 | 1363篇 |
1981年 | 1054篇 |
1980年 | 858篇 |
1979年 | 638篇 |
1978年 | 473篇 |
1977年 | 374篇 |
1976年 | 346篇 |
1975年 | 237篇 |
Research design and methods: This multicenter, open-label, single-group, prospective interventional study evaluated changes in total gait-related scores of the Part II/III Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and Freezing of Gait Questionnaire (FOG-Q) in 31 Parkinson’s disease patients treated with istradefylline. Gait analysis by portable gait rhythmogram was performed.
Results: MDS-UPDRS Part III gait-related total scores significantly decreased at Weeks 4–12 from baseline with significant improvements in gait, freezing of gait, and postural stability. Significant decreases in MDS-UPDRS Part II total scores and individual item scores at Week 12 indicated improved daily living activities. At Week 12, there were significant improvements in FOG-Q, new FOG-Q, and overall movement per 48 h measured by portable gait rhythmogram. Adverse events occurred in 7/31 patients.
Conclusions: Istradefylline improved gait disorders in Parkinson’s disease patients complicated with freezing of gait, improving their quality of life. No unexpected adverse drug reactions were identified.
Trial registration: UMIN-CTR (UMIN000020288). 相似文献
Median follow-up, length of pertuzumab/trastuzumab/taxane treatment and of pertuzumab, trastuzumab maintenance were 21, 4 and 15 months, respectively. The response rate was 77.3%, and the clinical benefit rate 93.6%. Median progression-free survival (mPFS) was 21 months, and median overall survival (mOS) was not reached.
When comparing patients by trastuzumab-pretreatment, similar PFS were observed, although a longer OS was reached in trastuzumab-naïve patients (p = 0.02). Brain metastases at baseline and their development in course of therapy were associated with significantly shorter PFS (p = 0.0006) and shorter OS, although at a not fully statistically relevant extent (p = 0.06).
The addition of maintenance endocrine therapy (ET) to pertuzumab/trastuzumab maintenance was associated with longer PFS (p = 0.0001), although no significant differences were detected in OS (p = 0.31). Results were confirmed by propensity score analysis (p = 0.003 and p = 0.46, respectively).
In multivariate models, longer PFS was related to lower Performance Status (PS) (p = 0.07), metastatic stage at diagnosis (p = 0.006) and single metastatic site (p < 0.0001). An OS advantage was observed with lower PS (p < 0.0001), single metastatic site (p = 0.004), no prior exposure to trastuzumab (p = 0.004) and response to pertuzumab-based treatment (p = 0.003). Our results confirm that trastuzumab/pertuzumab/taxane is the standard of care as first-line treatment of patients with HER2-positive ABC even in the real-world setting. Moreover, the double-maintenance therapy (HER2 block and ET) is strongly recommended when feasible. 相似文献